Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1643-1649

  Peters, Jette ^a   Block, Wiebke ^b   Oswald, Stefan ^a   Freyer, Johanna ^a   Grube, Markus ^a   Kroemer, Heyo K ^a   Lam̈mer, Marc ^b   Luẗjohann, Dieter ^c   Venner, Monica ^d   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Ernst Moritz Arndt University Greifswald ^*  (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Veterinary Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; 14BETA HYDROXYCHOLESTEROL; ABC TRANSPORTER; ABC TRANSPORTER C2; CHOLESTEROL; CHOLESTEROL DERIVATIVE; CLARITHROMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1; PREGNANE X RECEPTOR; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRONCHIAL EPITHELIAL LINING FLUID; BRONCHUS MUCOSA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENE EXPRESSION; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRONCHI; CHOLESTEROL; CLARITHROMYCIN; DRUG INTERACTIONS; EPITHELIAL CELLS; HORSES; HYDROXYCHOLESTEROLS; LUNG; MOUTH MUCOSA; ORGANIC ANION TRANSPORTERS; RECEPTORS, STEROID; RIFAMPIN; RNA, MESSENGER;

RHODOCOCCUS EQUI;

EID: 80051984480     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039206     Document Type: Article

References (40)

1. Bosquillon C. (2010) Drug transporters in the lung - Do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci 99:2240-2255.
2. Chan L.M., Lowes S, and Hirst B.H. (2004) The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51. (Pubitemid 38050202)
3. Conte J.E. Jr, Golden J.A., Duncan S., McKenna E, and Zurlinden E. (1995) Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 39:334-338.
4. Endter S., Francombe D., Ehrhardt C, and Gumbleton M. (2009) RT- PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J Pharm Pharmacol 61:583-591.
5. Garver E., Hugger E.D., Shearn S.P., Rao A., Dawson P.A., Davis CB, and Han C. (2008) Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat. Drug Metab Dispos 36:2492-2498.
6. Geick A., Eichelbaum M, and Burk O. (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
7. Giguère S., Jacks S., Roberts G.D., Hernandez J., Long MT, and Ellis C. (2004) Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia. J Vet Intern Med 18:568-573. (Pubitemid 39107551)
8. Glaeser H. (2011) Importance of P- Glycoprotein for drug- Glycoprotein for drugDrug interactions. Handb Exp Pharmacol 201:285-297.
9. Hagenbuch B and Meier P.J. (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/ functional properties. Pflugers Arch 447:653-665. (Pubitemid 38241451)
10. Handschin C and Meyer U.A. (2003) Induction of drug metabolism: The role of nuclear receptors. Pharmacol Rev 55:649-673. (Pubitemid 37504978)
11. Hillidge C.J. (1987) Use of erythromycin- Rifampin combination in treatment of Rhodococcus equi pneumonia. Vet Microbiol 14:337-342.
12. Hughes J and Crowe A. (2010) Inhibition of P- Glycoprotein- GlycoproteinMediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 113:315-324.
13. Jacks S., Giguère S., Gronwall P.R., Brown MP, and Merritt K.A. (2001) Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals. Am J Vet Res 62:1870-1875. (Pubitemid 33130532)
14. Jacks S.S., Giguère S, and Nguyen A. (2003) In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. Antimicrob Agents Chemother 47:1742-1745. (Pubitemid 36548565)
15. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., Tontonoz P., Kliewer S., Willson TM, and Edwards P.A. (2002) Regulation of multidrug resistance- Associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X- Associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid XActivated receptor, and constitutive androstane receptor. J Biol Chem 277:2908-2915. (Pubitemid 34953324)
16. Lan T., Rao A., Haywood J., Davis C.B., Han C., Garver E, and Dawson P.A. (2009) Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion- Transporting polypeptides. Drug Metab Dispos 37:2375-2382.
17. Lau Y.Y., Okochi H., Huang Y, and Benet L.Z. (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771. (Pubitemid 43131004)
18. Lim Y.P., Kuo S.C., Lai ML, and Huang J.D. (2009) Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator- 1, and hepatocyte nuclear factor 4alpha interaction. Pharmacogenet Genomics 19:11-24.
19. Meyer zu Schwabedissen H.E., Tirona R.G., Yip C.S., Ho RH, and Kim R.B. (2008) Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 68:9338-9347.
20. Moreau A., Le Vee M., Jouan E., Parmentier Y, and Fardel O. (2011) Drug transporter expression in human macrophages. Fundam Clin Pharmacol doi:10.1111/j.1472-8206.2010.00913.x.
21. Munić V., Kelnerić Z., Mikac L, and Eraković Haber V. (2010) Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P- Gp) using rhodamine- Gp) using rhodamine123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci 41:86-95.
22. Oswald S., Peters J., Venner M, and Siegmund W. (2011a) LC- MS/MS method for the simultaneous determination of clarithromycin, rifampicin and their main metabolites in horse plasma, epithelial lining fluid and broncho- MS/MS method for the simultaneous determination of clarithromycin, rifampicin and their main metabolites in horse plasma, epithelial lining fluid and bronchoAlveolar cells. J Pharm Biomed Anal 55:194-201.
23. Oswald S., Terhaag B, and Siegmund W. (2011b) In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P- Glycoprotein (ABCB1) in humans. Handb Exp Pharmacol 201:403-447.
24. Pachot J.I., Botham R.P., Haegele KD, and Hwang K. (2003) Experimental estimation of the role of P- Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco- Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco2 cell model. J Pharm Pharm Sci 6:1-12. (Pubitemid 37207237)
25. Rennard S.I., Basset G., Lecossier D., O'Donnell K.M., Pinkston P., Martin PG, and Crystal R.G. (1986) Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60:532-538. (Pubitemid 16019939)
26. Seithel A., Eberl S., Singer K., Auge D., Heinkele G., Wolf N.B., Dörje F., Fromm MF, and König J. (2007) The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 35:779-786. (Pubitemid 46641549)
27. Seral C., Carryn S., Tulkens PM, and Van Bambeke F. (2003a) Influence of P- Glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother 51:1167-1173. (Pubitemid 36622073)
28. Seral C., Michot J.M., Chanteux H., Mingeot-Leclercq M.P., Tulkens PM, and Van Bambeke F. (2003b) Influence of P- Glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob Agents Chemother 47:1047-1051. (Pubitemid 36254233)
29. Sugie M., Asakura E., Zhao Y.L., Torita S., Nadai M., Baba K., Kitaichi K., Takagi K., Takagi K, and Hasegawa T. (2004) Possible involvement of the drug transporters P glycoprotein and multidrug resistance- Associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 48:809-814. (Pubitemid 38280329)
30. Suzuki A., Iida I., Hirota M., Akimoto M., Higuchi S., Suwa T., Tani M., Ishizaki T, and Chiba K. (2003) CYP isoforms involved in the metabolism of clarithromycin in vitro: Comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metab Pharmacokinet 18:104-113.
31. Taki H., Ogawa K., Nakagawa T., Kashima K., Tarumi O., Saitou Y., Yamada N., Tano M, and Nikai T. (2007) [Clinical analysis of drug interaction between rifampicin and clarithromycin which are used for treating pulmonary Mycobacterium avium complex infection]. Kekkaku 82:641-646.
32. Tirona R.G. (2011) Molecular mechanisms of drug transporter regulation. Handb Exp Pharmacol 201:373-402.
33. Tomalik-Scharte D., Lütjohann D., Doroshyenko O., Frank D., Jetter A, and Fuhr U. (2009) Plasma 4′- Hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther 86:147-153.
34. Tydén E., Tallkvist J., Tjälve H, and Larsson P. (2009) P- Glycoprotein in intestines, liver, kidney and lymphocytes in horse. J Vet Pharmacol Ther 32:167-176.
35. Vavricka S.R., Van Montfoort J., Ha H.R., Meier PJ, and Fattinger K. (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172. (Pubitemid 34700774)
36. Venner M., Peters J., Höhensteiger N., Schock B., Bornhorst A., Grube M., Adam U., Scheuch E., Weitschies W., Rosskopf D., et al. (2010) Concentration of the macrolide antibiotic tulathromycin in broncho- Alveolar cells is influenced by comedication of rifampicin in foals. Naunyn Schmiedebergs Arch Pharmacol 381:161-169.
37. Wallace R.J. Jr, Brown B.A., Griffith D.E., Girard W, and Tanaka K. (1995) Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium- M. intracellulare infection. J Infect Dis 171:747-750.
38. Womble A.Y., Giguère S., Lee EA, and Vickroy T.W. (2006) Pharmacokinetics of clarithromycin and concentrations in body fluids and bronchoalveolar cells of foals. Am J Vet Res 67:1681-1686. (Pubitemid 44605284)
39. Yang Z and Rodrigues A.D. (2010) Does the long plasma half- Life of 4′- Life of 4′Hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? J Clin Pharmacol 50:1330-1338.
40. Zong J and Pollack G.M. (2003) Modulation of P- Glycoprotein transport activity in the mouse blood- Glycoprotein transport activity in the mouse bloodBrain barrier by rifampin. J Pharmacol Exp Ther 306:556-562. (Pubitemid 36886154)